Erratum: The JUPITER trial: Myth or reality? (Current Atherosclerosis Reports (2011) 13, 5, (417), 10.1007/s11883-011-0197-9);The JUPITER trial: Myth or reality?

Current Atherosclerosis Reports

Volumn 13, Issue 5, 2011, Pages 413-421

  Morrissey, Ryan P ^a   Diamond, George A ^a   Kaul, Sanjay ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

C reactive protein; Cardiovascular disease; Coronary heart disease; JUPITER; Myocardial infarction; Outcomes; Primary prevention; Statin; Stroke; Unstable angina

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG RESPONSE; DRUG SAFETY; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MORTALITY; PATIENT IDENTIFICATION; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 81055157965     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0204-1     Document Type: Erratum

References (43)

1. World Health Organization. World Health Statistics. Available at: http://www.who.int/whosis/whostat/EN-WHS08-Full.pdf. Accessed March 2011.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-44.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospectivemeta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
4. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
5. Food and Drug Administration. Highlights of prescribing information: Crestor (rosuvastatin calcium) tablets. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/2010/021366s016lbl. pdf. Accessed March 2011.
6. Michos ED, Blumenthal RS. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol. 2009;53:931-5.
7. Spatz ES, Canavan ME, Desai MM. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey. Circ Cardiovasc Qual Outcomes. 2009;2:41-8.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. (Pubitemid 28248586)
9. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation. 2009;120:2188-96.
10. Sever P. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. Presented at the American Heart Association 2010 Scientific Sessions. Chicago, USA; November 17, 2010.
11. Heart Protection Study Collaborative G. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study. Lancet. 2011;377:469-76.
12. Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 2010;170:1073-7.
13. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010;106:204-9.
14. Food and Drug Administration. CRESTOR (rosuvastatin calcium): briefing material-updated version. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193831.pdf. Accessed March 2011.
15. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175-82.
16. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. (Pubitemid 38477774)
17. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Matthew JF, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2010;56:2182-99.
18. DeMaria AN, DeLemos JA, Diamond GA, Greenland P, Gudnason V, Hachamovitch R, et al. Comparative efficacy of strategies for risk screening and prevention for cardiovascular disease. J Am Coll Cardiol. 2009;53:A220.
19. Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009;2:279-85.
20. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels-Ansdell D, Walter SD, Guyatt GH, Flynn DN, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010;303:1180-7.
21. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999;341:1789-94.
22. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839-47.
23. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having noncardiac surgery: a meta-analysis. Lancet. 2008;372:1962-76.
24. de Lorgeril M, Salen P, Abramson J, Dodin S, Hamazaki T, Kostucki W, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170:1032-6.
25. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet. 2009;373:1152-5.
26. Ridker PM, Glynn RJ. The JUPITER Trial: responding to the critics. Am J Cardiol. 2010;106:1351-6.
27. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
28. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
29. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769-81.
30. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307-13. (Pubitemid 44833354)
31. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;1:CD004816.
32. Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G. Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol. 2008;61:241-6.
33. Goodman SN. Stopping at nothing? Some dilemmas of data monitoring in clinical trials. Ann Intern Med. 2007;146:882-7. (Pubitemid 351650489)
34. Morrissey RP, Diamond GA, Kaul S. Bayesian approach to moderate implausible treatment effects observed in trials stopped early: lessons learnt from JUPITER trial. Circulation. 2010;122: A21109.
35. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170:1024-31.
36. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871-80. (Pubitemid 36875671)
37. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39. (Pubitemid 38924592)
38. Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circ Cardiovasc Qual Outcomes. 2009;2:616-23.
39. Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA. 1999;282:1899-901.
40. Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens. 1998;11:618-29. (Pubitemid 28270727)
41. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. (Pubitemid 41416583)
42. Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The costeffectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J Am Coll Cardiol. 2011;57:784-91.
43. Hlatky M. The cost-effectiveness of rosuvastatin therapy JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011;57:792-3.